Utilizing advanced technology for early detection of an ambulatory patient's changing condition, the new BeneVision TM70 Telemetry Transmitter expands coverage to the licensed and FCC-protected WMTS spectrum (1.4GHz), providing a versatile wearable monitoring solution across the hospital enterprise.
Mahwah, N.J. (PRWeb) March 01, 2021 -- Mindray North America, a global manufacturer of medical device solutions and technologies, today announced the release of the BeneVision TM70 Telemetry platform for the U.S. market. Taking full advantage of the licensed and FCC-protected Wireless Medical Telemetry Service (WMTS) spectrum, TM70 telemetry and the BeneVision Distributed Monitoring System (DMS) expand Mindray’s telemetry offering to the 1.4GHz bandwidth, further supporting continuous monitoring of ambulating patients and gap-free patient data to the Electronic Medical Record (EMR).
“The BeneVision TM70 puts groundbreaking telemetry technology within reach, placing exceptional performance, reliability and scalability into the hands of clinicians of high-volume telemetry and step-down departments,” said Michael Mullen, Senior Marketing Manager - Service and Support, Mindray North America. “Our flexible BeneVision telemetry offerings are now expanded to include protected WMTS TM70 telemetry and the 5GHz WiFi TM80 telemetry solution. Such flexibility in platform solutions is consistent with Mindray’s commitment to apply meaningful innovation to drive impactful results such as improved patient outcomes and increased staff productivity,” continued Mike.
Mindray telemetry, when paired with our industry-leading BeneVision N-Series patient monitoring solutions, allows all telemetry parameters to be viewed on the patient monitor even during ambulation, facilitating the patient’s return to health.
Using our ECG Mobility cable between Mindray bedside monitors and telemeters simplifies patient transitions as they progress from department to department. This “flexing” is quick and efficient, minimizing disruption to patients, thereby supporting a better patient experience. Whether pairing or flexing, a continuous stream of data is maintained, enabling a consistent and complete patient record across the healthcare enterprise.
An integral part of the BeneVision DMS solution, BeneVision TM70 empowers clinical decision-making at bedside, directly at the telemeter. This state-of-the-art telemetry platform incorporates design-driven patient safety attributes specific to the needs of ambulating patients such as real-time device location, local alarms and on-board arrhythmia detection. Furthermore, deployment of a ”virtual fence” to identify boundaries for mobilized patients, optimizes patient safety while efficiently managing an institution’s assets.
BeneVision TM70 telemetry is another excellent example of the constant innovation that is taking place at Mindray. Joining the likes of the N-Series patient monitoring series including the BeneVision N1 Transport Monitor/Module, and the industry-leading A-Series Advantage anesthesia systems, BeneVision TM70 provides a complete solution meeting the needs of not only clinicians, but also the technological demands of today’s complex healthcare systems.
Mindray is a leading developer, manufacturer and supplier of medical device solutions and technologies used in healthcare facilities around the globe. We believe we can change lives by making the most advanced healthcare technology attainable for all. We do this by empowering healthcare professionals through innovative, high-value solutions that help create the next generation of life-saving tools across three primary business segments: patient monitoring and life support, in-vitro diagnostics, and medical imaging. Mindray maintains its global headquarters in Shenzhen, China; Mindray North America is headquartered in Mahwah, New Jersey. Our Ultrasound Innovation Center is located in San Jose, California with additional facilities in major international markets around the world. For more information, please visit http://www.mindray.com.
Mindray North America